Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1770)	9/20/2007 11:27:33 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GNVC stock is up 3.7% after some comments about its paper on treatment of ovarian Ca. in the Oct. issue of Int.J. of Oncol. bigcharts.marketwatch.com GenVec Technology Demonstrates Selective Anti-Cancer Activity Thursday September 20, 8:00 am ET GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC - News) announced today the publication of pre-clinical research demonstrating the selective delivery of TNF-alpha to tumors. Combining a new, targeted adenovector with selective regulation of gene expression achieved a high degree of anti-tumor activity and selectivity in animal models of disseminated ovarian cancer. The paper, Experimental Treatment Of Ovarian Cancers By Adenovirus Vectors Combining Receptor Targeting And Selective Expression Of Tumor Necrosis Factor, authored by GenVec scientist Selva R. Murugesan, Ph.D., appears in the October issue of the International Journal of Oncology, (31: 813-822, 2007). It describes how GenVec technology was used to modify the structure of adenovectors to control both their ability to selectively bind to ovarian cancer cells and enhance the expression of TNF alpha protein in tumor cells. Results demonstrated that the modified adenovector induced anti-tumor responses and limited expression of TNF in normal tissue. These highly selective adenovectors may provide the basis for a potentially safe and effective treatment for cancers of the peritoneal space including ovarian and stomach cancers. "Our new generation adenovector uses a combination of technologies which enable targeted delivery of our drug specifically to the tumor and control of gene expression within the tumor cells, avoiding toxicity in surrounding healthy tissue. This is an excellent example of how GenVec's technology can be applied to provide new treatment strategies," commented C. Richter King, Ph.D., GenVec's Senior Vice President of Research. Snip The stock needs to close above the Aug 14 H of $2.60 before it can get off from the down trend coming from its June H & think about closing its June 4 DG.<g> bigcharts.marketwatch.com Bernard